ライフサイエンスコーパス: vaccine candidate

1 tive-like structure, supporting its use as a vaccine candidate.

2 an animal model, making it a leading malaria vaccine candidate.

3 m smegmatis called IKEPLUS is a promising TB vaccine candidate.

4 ted in infective sporozoites 3 (PfUIS3) as a vaccine candidate.

5 ss-reactive antigen 1 (Pca1), as a potential vaccine candidate.

6 ts with the parasite ligand Rh5, a prominent vaccine candidate.

7 promising tetravalent Dengue virus sub-unit vaccine candidate.

8 n expressed in gametocytes is an alternative vaccine candidate.

9 means for large-scale production of this HCV vaccine candidate.

10 hat S-FLU is a promising universal influenza vaccine candidate.

11 These features make PvRMC-MSP1 a promising vaccine candidate.

12 otective efficacy using a broadly protective vaccine candidate.

13 the RSV F protein represent a promising RSV vaccine candidate.

14 BC invasion, BmAMA1 should be evaluated as a vaccine candidate.

15 ing immunity will be needed for a successful vaccine candidate.

16 Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate.

17 rther supports the potential of EBA-175 as a vaccine candidate.

18 e conjugative plasmid pIP501, as a potential vaccine candidate.

19 the design of new HIV-1 sequential envelope vaccine candidates.

20 ation site may facilitate design of improved vaccine candidates.

21 d to design effective attenuated viruses for vaccine candidates.

22 access to potential self-adjuvant anticancer vaccine candidates.

23 -free virus, they are not induced by current vaccine candidates.

24 al gene to develop disabled virus strains as vaccine candidates.

25 ribute to the pathogenesis of infection, and vaccine candidates.

26 djuvant for immunoprophylactic schistosomula vaccine candidates.

27 the glycan epitopes presented on recombinant vaccine candidates.

28 on nanoparticles may thus provide promising vaccine candidates.

29 g studies in order to prioritize blood stage vaccine candidates.

30 ll immunity is the main target of current TB vaccine candidates.

31 parameters, which are essential criteria for vaccine candidates.

32 oof-of-concept testing of future blood-stage vaccine candidates.

33 bacterial-derived small molecules are prime vaccine candidates.

34 rategy for identifying peanut T-cell peptide vaccine candidates.

35 hould be considered when developing new hRSV vaccine candidates.

36 istosomulum should be considered as possible vaccine candidates.

37 ing immune responses and represent promising vaccine candidates.

38 nvironmental safety of live tick-borne virus vaccine candidates.

39 play these fingers, they may have utility as vaccine candidates.

40 used for the development of safe and stable vaccine candidates.

41 immunogen evaluation pipeline to rank-order vaccine candidates.

42 outbreak led to accelerated efforts to test vaccine candidates.

43 assessment of antibody-mediated therapies or vaccine candidates.

44 nto foreign VLP systems to generate anti-RSV vaccine candidates.

45 n is important in guiding the development of vaccine candidates.

46 ave the potential to be investigated as live vaccine candidates.

47 roach this ideal and are therefore plausible vaccine candidates.

48 valuation in additional studies as potential vaccine candidates.

49 sed as a novel method to down-select between vaccine candidates.

50 can provide selection criteria to rank order vaccine candidates.

51 , provides insights to advance design of HIV vaccine candidates.

52 generation, live-attenuated, recombinant JEV vaccine candidates.

53 ion in evaluating the efficacy of gonococcal vaccine candidates.

54 different designs that are being assessed as vaccine candidates.

55 (IPD) is a valuable approach to define novel vaccine candidates.

56 rategy to transition from panels of bnAbs to vaccine candidates.

57 a potential strategy for the design of HIV-1 vaccine candidates.

58 are used for preclinical evaluation of HIV-1 vaccine candidates.

59 basis of a new generation of live attenuated vaccine candidates.

60 he wild-type HA from viruses selected as the vaccine candidates.

61 ce of Bp and Bm lipopolysaccharides (LPS) as vaccine candidates.

62 ability and natural antigenicity to serve as vaccine candidates.

63 production of two different AMA1-DiCo-based vaccine candidates.

64 atively impact the sequence stability of the vaccine candidates.

65 eed for further improvements to evaluate HIV vaccine candidates.

66 timal substitutions provides live attenuated vaccine candidates.

67 nerally to improve efficacy of other malaria vaccine candidates.

68 obstacle for the development of nonlive RSV vaccine candidates.

69 udies can yield improved synthetic RNA virus vaccine candidates.

70 uld facilitate development of effective hMPV vaccine candidates.

71 hallenges facing clinical evaluation of ZIKV vaccine candidates.

72 table to support the development of P. vivax vaccines candidates.

73 icidal monoclonal Ab (mAb) 2C7, a gonococcal vaccine candidate Ab, attenuates vaginal colonization by

74 d GII.4c norovirus virus-like particle (VLP) vaccine candidate adjuvanted with alum and monophosphory

75 Additionally, vaccine candidates adjuvanted by a robust formulation of

76 e also examined the in vivo stability of the vaccine candidates after a single passage in African gre

77 y stable, highly immunogenic, and protective vaccine candidate against Bolivian hemorrhagic fever.

78 ment as a production site for an EDIII-based vaccine candidate against dengue fever and presents a Ga

79 vers, demonstrating that TraM is a promising vaccine candidate against enterococci and other gram-pos

80 , the fused vaccine is a promising trivalent vaccine candidate against HEV, RV, and AstV, which is wo

81 porting that PPTSP44 constitutes a promising vaccine candidate against human leishmaniasis.

82 ese reasons, these vectors can be considered vaccine candidates against HIV/AIDS and currently are be

83 cquired relevant immunological properties as vaccine candidates against HIV/AIDS, and the viral B19 m

84 ased approach for developing live-attenuated vaccine candidates against human-pathogenic arenaviruses

85 in humans, therefore constituting potential vaccine candidates against leishmaniasis.

86 n1(-/-) and Ldp27(-/-) are promising as live vaccine candidates against VL since they elicit strong p

87 Vaccine candidates against ZIKV are coming online, but i

88 eing developed for structural studies and as vaccine candidates aimed at the induction of broadly neu

89 ant spike protein or inactivated whole-virus vaccine candidates alone or adjuvanted with either alum,

90 C virus (HCV) lipid envelope is a potential vaccine candidate and antiviral target.

91 RTS,S is an advanced malaria vaccine candidate and confers significant protection aga

92 e, we generated a live attenuated avian H3N8 vaccine candidate and demonstrated that a single dose of

93 We generated a live attenuated H3N8 vaccine candidate and demonstrated that the vaccine was

94 irus-like particles (VLPs) are an attractive vaccine candidate and induce antibodies, but T cell resp

95 e immunogenic version of this well-tolerated vaccine candidate and should be applicable to other vect

96 inant virus is a safe and effective bivalent vaccine candidate and that the expression of both F and

97 aneously with the glycoprotein-based subunit vaccine candidate and then subjected to heterologous cha

98 Identification of the best vaccine candidates and evaluation of their performance i

99 n of interest, have been used to down-select vaccine candidates and have provided efficacy data in su

100 ovide a framework for the design of new EBOV vaccine candidates and immunotherapies.

101 experimental evidence, from pre-erythrocytic vaccine candidates and irradiated sporozoites, has shown

102 In this review, we discuss the vaccine candidates and key factors shaping the developme

103 understanding of Env will translate into new vaccine candidates and more-effective antiretroviral the

104 In this work, we characterized the new vaccine candidates and tested their efficacies in both m

105 or evaluating protective efficacy of HIV/SIV vaccine candidates and that TFH cells play a pivotal rol

106 valuate the emerging G9 strains as potential vaccine candidates and to test the susceptibility of var

107 r, we identified LSA3 as a novel blood-stage vaccine candidate, and we propose that this system will

108 ponses, to more globally differentiate among vaccine candidates, and most critically, to identify the

109 tein is considered one of the most promising vaccine candidates, and recent evidences suggest that th

110 has recently been identified as a promising vaccine candidate antigen on the bacterial surface of M.

111 asion ligand that is a potential blood-stage vaccine candidate antigen; however, a naturally occurrin

112 protective responses and identify chlamydial vaccine candidate antigens.

113 ics was prioritized to fuel the discovery of vaccine candidate antigens.

114 tential of humoral responses against malaria vaccine candidate antigens.

115 ly assessing neutralizing antibodies against vaccine-candidate antigens in regions with varying malar

116 d Abs specific for the Plasmodium falciparum vaccine candidate apical membrane Ag-1 (AMA1) in HIV-inf

117 reted in T-cell assays, we have identified 4 vaccine candidate Ara h 1 peptides.

118 Currently, several RSV vaccine candidates are under development to target diffe

119 l protein 1 (NS1) has long been considered a vaccine candidate as it avoids Ab-dependent enhancement.

120 Here, we describe a broadly protective vaccine candidate based on chimeric hemagglutinins, cons

121 Here, we describe the evaluation of an EBOV vaccine candidate based on Kunjin replicon virus-like pa

122 this article, we describe a new tetravalent vaccine candidate based on recombinant dengue virus caps

123 pment of safe and protective live attenuated vaccine candidates based on genome reorganization for th

124 sponses induced by P. falciparum or P. vivax vaccine candidates based on MSP119 have not been reporte

125 his study, we developed recombinant bivalent vaccine candidates based on recombinant vaccine strain r

126 oxvirus vectors could be considered HIV/AIDS vaccine candidates based on their activation of potentia

127 raction assays using a transmission-blocking vaccine candidate, BBA52, as bait identified an interact

128 RH5 is a leading subunit vaccine candidate because anti-RH5 antibodies inhibit pa

129 423 of the viral E2 glycoprotein is a valid vaccine candidate because antibodies recognizing this re

130 PfRH5 is a leading blood-stage vaccine candidate because it exhibits limited polymorphi

131 irus-like particles (VLPs) are an attractive vaccine candidate because they are noninfectious and eli

132 Live attenuated viruses are attractive vaccine candidates because they can elicit both humoral

133 escape variants and the selection of future vaccine candidates before they become widespread in natu

134 tial of the novel, live attenuated pertussis vaccine candidate BPZE1.

135 e results indicate that VLPs are a promising vaccine candidate but do not prevent lung TCD8 impairmen

136 se results suggest that VLPs are a promising vaccine candidate but do not prevent lung TCD8 impairmen

137 only demonstrate that sE2 is a promising HCV vaccine candidate, but also highlight the importance of

138 Serotype 35B is thus a likely future vaccine candidate, but due to their previous rarity, ser

139 tional importance, DBP is considered a prime vaccine candidate, but variation in B-cell epitopes at t

140 ble Env trimers have become attractive HIV-1 vaccine candidates, but the prototype designs are capabl

141 s work, our goal was to improve the original vaccine candidate by modifying the PIV5 vector or by mod

142 s that remained to be separated from the two vaccine candidates (by 34% and 13%, respectively), thus

143 These results suggest that future TB vaccine candidates can be developed on the basis of MtbD

144 size the need to investigate a pediatric RSV vaccine candidate carefully for priming of ERD over a wi

145 A bivalent intranasal RSV/HPIV3 vaccine candidate consisting of a chimeric bovine/human

146 to the characterization of a glycoconjugate vaccine candidate consisting of a genetically detoxified

147 demonstrate that live-attenuated Zika virus vaccine candidates containing deletions in the 3' untran

148 Our analysis suggests that the potential vaccine candidates could reduce total fluke burden and e

149 These T1D vaccine candidates could therefore represent an expedien

150 The resultant vaccine candidate, DB1, was attenuated, highly immunogen

151 compared to those of a previously described vaccine candidate deleted for ORF56 and ORF57 (Delta56-5

152 plaque phenotype in two dengue virus (DENV) vaccine candidates, DENV-3 PGMK30FRhL3, which produced a

153 eview, we focus on the Sanofi Pasteur dengue vaccine candidate, describing the steps from research to

154 Here, we constructed five vaccine candidates, designated 2012-RBD, 2013-RBD, 2014-

155 nant vesicular stomatitis virus (rVSV)-based vaccine candidate designed to prevent EVD.

156 vel generation of improved DNA-C and NYVAC-C vaccine candidates designed for higher expression levels

157 e that this system will be useful for future vaccine candidate discovery.

158 nderscore the need to evaluate a nonlive RSV vaccine candidate during preclinical development over a

159 Current HIV-1 envelope glycoprotein (Env) vaccine candidates elicit predominantly tier 1 and/or au

160 This Ebola vaccine candidate elicited anti-Ebola antibody responses

161 Emergency of International Concern, multiple vaccine candidates entered clinical trials, now totaling

162 ars ago, there have been no new tuberculosis vaccine candidates entering clinical testing.

163 Antibodies to the major invasion ligand and vaccine candidate, erythrocyte-binding antigen 175 (EBA-

164 dentified an attenuated and immunogenic i.n. vaccine candidate expressing GP from the pre-N position.

165 ion with a parainfluenza virus 5 recombinant vaccine candidate expressing NA (PIV5-NA) from a pandemi

166 ind, dose-escalation trials of an rVSV-based vaccine candidate expressing the glycoprotein of a Zaire

167 ated a parainfluenza virus 5 (PIV5)-vectored vaccine candidate expressing the RSV fusion protein (F)

168 el replicating poxvirus NYVAC-based HIV/AIDS vaccine candidates expressing clade C HIV-1 antigens, wi

169 We have generated two novel NYVAC-based HIV vaccine candidates expressing HIV-1 clade C trimeric sol

170 nlB prfA* (LmIII), we constructed five rLm30 vaccine candidates expressing r30 linked in frame to the

171 These features make PvRMC-CSP a promising vaccine candidate for further development.

172 6150 appears safe and a promising preventive vaccine candidate for HCV infection.

173 C vector could be a novel optimized HIV/AIDS vaccine candidate for human clinical trials.

174 inding Protein (PvDBP) is the most promising vaccine candidate for P. vivax malaria.

175 vaccine, the Deltacps1 strain is a promising vaccine candidate for preventing coccidioidomycosis in h

176 and therefore represents a new and promising vaccine candidate for the global fight against ZIKV.

177 This suggests that MBC4 is a suitable vaccine candidate for the simultaneous treatment of Bet

178 Adenovirus vectors are widely used as vaccine candidates for a variety of pathogens, including

179 To date, most therapeutic and vaccine candidates for human immunodeficiency virus type

180 are currently undergoing clinical trials as vaccine candidates for many diseases.

181 combinant adenoviral vectors (rAds) are lead vaccine candidates for protection against a variety of p

182 be considered when designing and testing TB vaccine candidates for these populations.

183 V fusion protein nanoparticle vaccine (RSV F vaccine) candidate for maternal immunization was tested

184 d protein D (PhtD), an S. pneumoniae adhesin vaccine candidate, for its ability to prevent invasive S

185 bivalent norovirus virus-like particle (VLP) vaccine candidate formulations in healthy adults aged 18

186 biophysical properties of other recalcitrant vaccine candidates from emerging pathogens.

187 Many promising vaccine candidates from pathogenic viruses, bacteria, an

188 ross-reactive epitopes is critical to moving vaccine candidates from preclinical animal studies to cl

189 Furthermore, the ZIKV-3'UTR-LAV vaccine candidates have a desirable safety profile.

190 public health threat, no safe and efficient vaccine candidates have been developed to date.

191 the subunit approach; however, many subunit vaccine candidates have had limited efficacy in settings

192 clinical studies of viral vector-based HIV-1 vaccine candidates have previously shown partial protect

193 Several Zika virus (ZIKV) vaccine candidates have recently been described which us

194 ion and suboptimal immunogenicity of malaria vaccine candidates have slowed the development of a Plas

195 Vaccine candidates have so far failed to induce such ant

196 e)vaccination with the adjuvanted HZ subunit vaccine candidate (HZ/su) induced comparable immune resp

197 ata indicated that PIV5/F is a promising RSV vaccine candidate.IMPORTANCE A safe and efficacious resp

198 lopment of safer and genetically more stable vaccine candidates.IMPORTANCE Foot-and-mouth disease (FM

199 t HeV infections and would make an excellent vaccine candidate in areas where both RABV and henipavir

200 ian to human, but passage of a human-derived vaccine candidate in chicken eggs can select for reversi

201 ever, given the recent failures of such a TB vaccine candidate in clinical trials, strategies to harn

202 duction systems to generate a dengue subunit vaccine candidate in tobacco.

203 The majority of vaccine candidates in clinical development are highly pu

204 With few Schistosoma vaccine candidates in clinical trials, unexplored antige

205 ns within the genes Ech_0379 and Ech_0660 as vaccine candidates in deer and dogs.

206 not accurately reflect the effectiveness of vaccine candidates in humans that have preexisting immun

207 ntific and operational challenges, there are vaccine candidates in late-stage clinical development fo

208 rmore, C-prM-E and prM-E VLPs were tested as vaccine candidates in mice and compared to DNA vaccinati

209 The number of malaria vaccine candidates in preclinical and clinical developme

210 nuated vaccines (LAVs) are the most advanced vaccine candidates in RSV-naive infants.

211 y used to assess efficacy of preerythrocytic vaccine candidates in small proof-of-concept phase 2a cl

212 ized human respiratory syncytial virus (RSV) vaccine candidates in the context of strong selective pr

213 To investigate the stability of the vaccine candidates in vitro, they were passaged in Vero

214 e clinical development and licensure of Zika vaccine candidates including a discussion of clinical st

215 38G mutant has several features for an ideal vaccine candidate, including significantly reduced neuro

216 ys and humans within 6 months by several Env vaccine candidates, including gp120 monomers.

217 The attenuated vaccine candidate is expected to be safe and immunogenic

218 The leading pre-erythrocytic vaccine candidate is RTS,S, and early results of ongoing

219 referred conformation, and a current leading vaccine candidate is the BG505 DS-SOSIP variant, compris

220 A well-characterized vaccine candidate is the circumsporozoite protein (CSP).

221 ment of this promising, live-attenuated ZIKV vaccine candidate is warranted.

222 s suboptimal dosing of several RSV F subunit vaccine candidates led to the priming for ERD.

223 SP-1, which is a homologue of the Leishmania vaccine candidate leishmanolysin (GP63).

224 These RBD-based vaccine candidates maintained good functionality, antige

225 Therefore, this new vaccine candidate may not carry the risk for disease enh

226 Efforts to develop second-generation vaccine candidates may concentrate on adjuvants that mod

227 n liver failure and cancer and to prioritize vaccine candidates more efficiently, small-animal models

228 opeptidome of Jurkat cells infected with the vaccine candidate MVA.HIVconsv, which delivers HIV-1 con

229 The volunteers were given a prophylactic vaccine candidate (n = 7) or placebo (n = 5) and then ch

230 The most effective vaccine candidate of malaria is based on the Plasmodium

231 iation in invasion phenotypes and prioritize vaccine candidates on a relevant evidence base, we need

232 hAd63-MVA PfUIS3 was coadministered with the vaccine candidate P. falciparum thrombospondin-related a

233 In this review, we will examine why parasite vaccine candidates perform poorly in target populations

234 lciparum proteins, including the established vaccine candidate PfMSP1.

235 his approach using the transmission-blocking vaccine candidate Pfs25.

236 A vaccine candidate, PorB induces antibody responses that

237 This vaccine candidate preserved structural elements of the n

238 nces in Zika immunity and the development of vaccine candidates provide cautious optimism that preven

239 f immunocompetent mice with the MVA-ZIKV-NS1 vaccine candidate provided robust humoral and cellular r

240 mental in determining which of the many ZIKV vaccine candidates provides the highest degree of protec

241 ication by a simplified process to produce a vaccine candidate providing broad antiviral humoral and

242 g biological mechanisms elicited by the rBCG vaccine candidate relevant to its protective efficacy.

243 However, NS2-deleted RSV vaccine candidates rendered RSV overattenuated or poorly

244 Screening of vaccine candidates requires suitable panels of glycoprot

245 This vaccine candidate, RSV-A2-dNS-DeltaSH-BAF (DB1), was att

246 nation and challenge experiments proved this vaccine candidate's protective efficacy in pigs and the

247 This group of vaccine candidates shares an ability to potently induce

248 These vaccine candidates should have a low risk of deattenuati

249 The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the vaccine

250 e potential of the three forms as attenuated vaccine candidates, strain 4295 was inoculated intranasa

251 This provides an improved vectored RSV vaccine candidate suitable for pediatric clinical evalua

252 Our immunogens are therefore prototypes of vaccine candidates targeting the V1V2 region of HIV-1 En

253 ve attenuated recombinant tetravalent dengue vaccine candidate (TDV) given in 2 doses 90 days apart.

254 e attenuated, recombinant tetravalent dengue vaccine candidate (TDV) were evaluated in healthy volunt

255 analyses at 6 months of a tetravalent dengue vaccine candidate (TDV), which is comprised of an attenu

256 Most subunit vaccine candidates tested in clinical trials have provid

257 Here we report on a live-attenuated vaccine candidate that contains a 10-nucleotide deletion

258 Here, we describe a novel Dengue vaccine candidate that contains truncated, recombinant,

259 be here a novel approach to generate a PRRSV vaccine candidate that could confer unprecedented levels

260 s represents a safe, efficacious, whole-EBOV vaccine candidate that differs from other EBOV vaccine p

261 oyed RNA nanoparticle technology to create a vaccine candidate that elicited ZIKV E protein-specific

262 the previously well-tolerated rB/HPIV3-RSV F vaccine candidate that induces a superior RSV-neutralizi

263 dentified a promising broadly protective HCV vaccine candidate that should be considered for further

264 dentified an effective ST2 neoglycoconjugate vaccine candidate that was identified using a medicinal

265 target of neutralizing antibodies, Env-based vaccine candidates that address such diversity are neede

266 oited for the development of attenuated FMDV vaccine candidates that are safer and more stable than s

267 Yet to date, TB vaccine candidates that boost antigen-specific CD4 T cel

268 tudy, we developed and evaluated two subunit vaccine candidates that consisted of the same protruding

269 When HIV-1 vaccine candidates that include soluble envelope glycopr

270 d two parainfluenza virus 5 (PIV5)-based RSV vaccine candidates that protect mice against RSV challen

271 e become important components of the subunit vaccine candidates that we are currently developing.

272 Of the erythrocytic stage vaccine candidates, the 19 kDa fragment of the P. vivax

273 gmatic approaches to the clinical testing of vaccine candidates, the field has promise for delivering

274 evaluation of G9 strains as potential novel vaccine candidates to be included in porcine or human va

275 ment of novel therapeutics, diagnostics, and vaccine candidates to combat diseases caused by Bp and B

276 Most vaccine candidates to date have been ineffective at gene

277 ress three different AMA1-DiCo-based malaria vaccine candidates to develop a vaccine cocktail.

278 epitopes, which indicated their potential as vaccine candidates to induce stalk-specific antibodies.

279 Currently, many groups are testing influenza vaccine candidates to meet the challenge of developing a

280 nes of AMPV subtype-C (AMPV-C) as a bivalent vaccine candidate using reverse genetics technology.

281 falciparum CHMI model to assess blood-stage vaccine candidates, using their impact on the parasite m

282 C virus [HCV] genotype 1a) gpE1/gpE2 (E1E2) vaccine candidate was previously shown by our group to p

283 TATION: This tetravalent E coli bioconjugate vaccine candidate was well tolerated and elicited functi

284 To improve our previous vaccine candidate, we developed four new candidates that

285 fore, to improve on our previously developed vaccine candidate, we inserted RSV F at the PIV5 SH-HN g

286 To identify novel blood-stage malaria vaccine candidates, we constructed a library of 1,827P.

287 To test the immunogenicity of the vaccine candidates, we immunized mice intramuscularly wi

288 Animals immunized with a vaccine candidate were uniformly protected from lethal i

289 teins not previously recognized as potential vaccine candidates were also differentially recognized.

290 his study, novel, broadly reactive influenza vaccine candidates were assessed in preimmune ferrets.

291 st importantly, we found that PIV5-based RSV vaccine candidates were efficacious in preventing lower

292 the PIV5-RSV-F (HN-L) candidate, additional vaccine candidates were generated in which the gene for

293 The Towne/Toledo chimera vaccine candidates were well tolerated and were not excr

294 PfSPZ-CVac is a highly efficacious vaccine candidate; when we are able to optimize the immu

295 he protein and therefore can be exploited as vaccine candidates, where slow antigen release over exte

296 s induced by a single dose of the rVSV-ZEBOV vaccine candidate, which showed significant protective e

297 n assays in order to evaluate potential SAT2 vaccine candidates with improved stability.

298 hts into how to design and deliver effective vaccine candidates with properties to exert local immuno

299 ved version of this well-tolerated RSV/HPIV3 vaccine candidate, with potently improved immunogenicity

300 imers (SOSIP.664 gp140) are attractive HIV-1 vaccine candidates, with structures that mimic the nativ